NCT04523103

Brief Summary

Fertilization failure is a common problem in assisted reproductive Technology (ART). The main reason for fertilization failure of conventional IVF fertilization is sperm penetration failure, and the main reason of ICSI is insufficient oocyte activation. Artificial assisted activation may provide an effective technique to rescue fertilization failure. In this study, standard ICSI procedures were applied to save fertilization failure of unfertilized mature oocytes in IVF cycles. The unfertilized mature oocytes after ICSI were activated by calcium ion, or injected with calcium chloride/activated with mechanical stimulated and then transfer to calcium ion to improve fertilization. In this study, different artificial assisted activation methods were used to save the fertilization failure and assess its effective and subsequent embryo development potential.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2020

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 19, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 21, 2020

Completed
2 months until next milestone

Study Start

First participant enrolled

November 1, 2020

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2021

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2021

Completed
Last Updated

September 18, 2020

Status Verified

September 1, 2020

Enrollment Period

5 months

First QC Date

August 19, 2020

Last Update Submit

September 17, 2020

Conditions

Keywords

fertilization failure, oocyte activation, calcium ionophore

Outcome Measures

Primary Outcomes (1)

  • the normal fertilization rate

    Fertilization (2PN rate)

    12 months

Secondary Outcomes (3)

  • the good-quality embryo rate

    12 months

  • the blastocyst formation rate

    12 months

  • the good quality blastocyst rate

    12 months

Study Arms (4)

Control group

NO INTERVENTION

Standard ICSI procedure. The MII oocytes that failed fertilization in IVF cycles were injected with activating sperm.

A1 assisted activation

EXPERIMENTAL

The MII oocytes that failed fertilization in ICSI cycles were activated in calcium ionophore A23187 activation solution for two times.

Behavioral: Artificial Assisted Activation

A2 assisted activation

EXPERIMENTAL

Fertilization failure MII oocytes were collected in ICSI cycles. After CaCl2 was injected, the oocytes were transferred into the calcium ionophore A23187 solution for two times.

Behavioral: Artificial Assisted Activation

A3 assisted activation

EXPERIMENTAL

Fertilization failure MII oocytes were collected in ICSI cycles. Mechanical activation was done for the MII oocytes, and then the oocytes were transferred into the calcium ionophore A23187 solution for two times.

Behavioral: Artificial Assisted Activation

Interventions

Artificial assisted activation represents an effective technique to rescue the fertilization failure.

A1 assisted activationA2 assisted activationA3 assisted activation

Eligibility Criteria

Age25 Years - 35 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • ≤ Number of retrieved oocytes ≤ 20;
  • \< Body Mass Index (BMI) \<25;
  • The patients who suffered complete fertilization failure or low fertilization after performing standard ICSI/IVF cycle. Low fertilization was defined as less than 33% fertilization rate.

You may not qualify if:

  • Normal fertilization IVF/ICSI cycle.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tangdu Hospital

Xi'an, Shaanxi, 710038, China

Location

Study Officials

  • Li Bo, Doctor

    Reproductive Medicine Center, Tangdu Hospital

    STUDY CHAIR

Central Study Contacts

Wang Ming, Master

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 19, 2020

First Posted

August 21, 2020

Study Start

November 1, 2020

Primary Completion

March 31, 2021

Study Completion

September 30, 2021

Last Updated

September 18, 2020

Record last verified: 2020-09

Locations